Why CSL Limited shares look a great long-term bet

CSL Limited (ASX:CSL) is in a position to grow substantially over 10 years.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Blood plasma product and vaccine researcher CSL Limited (ASX: CSL) released its Investor R&D (Research and Development) Presentation to the market this morning. Some of it will go straight over the heads of investors without medical knowledge (including myself), but there are a few useful takeaways.

First, is the company's research projects:

source: Company presentation
source: Company presentation (click to enlarge)

At a glance, readers can see just how many products are in the works. A reasonable rule of thumb for the layperson would be to expect treatments to spend one year or more in each phase, with sales beginning in phase IV. As we can see, a number of treatments will be progressing from Phase III and Registration into the sales phase over the next year or two.

Second, we can see where the money is being spent:

Source: Company presentation
Source: Company presentation (click to enlarge)

Not only has CSL's expenditure on R&D increased, most of it goes to new product development. I suspect this actually means that CSL's growth is slowing. The resources allocated to new product research and existing product management have increased drastically, while 'market development' (expanding into new countries and finding new uses for existing treatments) is shrinking. This could suggest CSL has reached most major markets with its current products.

CSL also provided updates on a number of its clinical trials and new treatments (too many to list), although some of them such as CSL112 and a treatment designed to minimise the risk of rejection for donated (transplanted) organs have application and growing demand that will be obvious to the layperson.

Foolish takeaway

CSL's growth may be slowing. Yet the company also has a very strong product pipeline, and we can see that some of its current treatments, such as Gardasil (approved in 2006 but licensed to Merck & Co) and Privigen (approved in 2008) have very long lifespans. They are are also still big players in their respective markets.

Once the company successfully develops its treatments, it has a niche which competitors can't match without lots of time, research, and expenditure. Meanwhile, CSL is able to earn attractive returns on its investment for all of those years. Share prices will be volatile, as always, but CSL appears to have a strong future ahead of it.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »